Synthaverse S.A. Logo

Synthaverse S.A.

Develops and sells oncology, hematology, and immunology drugs and vaccines globally.

BML | WAR

Overview

Corporate Details

ISIN(s):
PLBMDLB00018 (+3 more)
LEI:
259400OWZM67D079S374
Country:
Poland
Address:
LUBLIN UNIWERSYTECKA 10, 20-029 LUBLIN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Synthaverse S.A. is a pharmaceutical and biotechnology company with a history dating back to 1944. The company develops, manufactures, and sells medicinal products (both prescription and OTC), medical devices, and laboratory reagents. Its portfolio focuses on treatments in the areas of oncology, hematology, and immunology, with products sold in approximately 50 countries. Key brands include Onko BCG, a drug for bladder cancer, and the BCG 10 anti-tuberculosis vaccine, for which the company is the sole supplier in Poland. Synthaverse emphasizes the use of its own proprietary technologies and close cooperation with scientific centers to drive research and innovation.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-20 15:38
Registration Form
zal01_Zal_STATUT_tekst_jedn._na_28.08.2025-1.pdf
Polish 688.4 KB
2025-11-20 15:38
Registration Form
Rejestracja przez sąd zmiany statutu emitenta - Content (PL)
Polish 9.1 KB
2025-11-19 14:30
Report Publication Announcement
Zmiana daty przekazania raportu kwartalnego za okres III kwartału 2025 roku - C…
Polish 952 bytes
2025-11-13 16:45
Regulatory News Service
Otrzymanie istotnej informacji o rejestracji na terytorium Holandii produktu le…
Polish 1.4 KB
2025-11-05 16:57
Legal Proceedings Report
Informacja o uchyleniu przez sąd zabezpieczenia roszczenia - Content (PL)
Polish 2.7 KB
2025-10-23 10:26
Director's Dealing
zal01_pdf_887150.pdf
Polish 9.0 KB
2025-10-23 10:26
Director's Dealing
Powiadomienie o transakcji na akcjach Emitenta - Content (PL)
Polish 349 bytes
2025-10-16 12:18
Regulatory News Service
Podpisanie protokołu odbioru linii technologicznej w Zakładzie produkcyjnym Onk…
Polish 2.1 KB
2025-09-30 22:10
Audit Report / Information
zal03_Synthaverse_30.06.2025_Raport_z_przegladu_srodrocznego_skroconego_JSF_MSS…
Polish 398.4 KB
2025-09-30 22:10
Management Discussion and Analysis
zal02_sprawozdanie_zarzadu_z_dzialalnosci_spolki_za_I_polrocze_2025.pdf
Polish 1.5 MB
2025-09-30 22:10
Interim Report
zal01_skrocone_srodroczne_sprawozdanie_finansowe_za_okres_od_01_01_2025_do_30_0…
Polish 2.7 MB
2025-09-29 08:35
Regulatory News Service
Zawarcie istotnej umowy handlowej - Content (PL)
Polish 5.2 KB
2025-09-17 14:03
Legal Proceedings Report
Informacja o wniesieniu powództwa o uchylenie lub stwierdzenie nieważności uchw…
Polish 4.1 KB
2025-09-08 08:48
Regulatory News Service
Zatwierdzenie przez Prezesa URPL zwiększenia wielkości serii Onko BCG 100 - Con…
Polish 1.6 KB
2025-08-27 15:08
Share Issue/Capital Change
Zawarcie umowy objęcia akcji serii W - Content (PL)
Polish 1.9 KB

Automate Your Workflow. Get a real-time feed of all Synthaverse S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Synthaverse S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Synthaverse S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden
ACTI
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America
ACTU
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden
ACUC
Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America
ACXP
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America
ADAG
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea
179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America
ADCT
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET

Talk to a Data Expert

Have a question? We'll get back to you promptly.